The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Anne Elizabeth Samuel - JPMorgan Chase & Co, Research Division - Analyst
: Congrats on the nice quarter. As we think about provider client growth, how should we be thinking about the length of your sales cycle? And is
there still any lingering carryover from COVID disruption that happen in March and April that might kind of still be impacting that number as we
look forward?
Question: Anne Elizabeth Samuel - JPMorgan Chase & Co, Research Division - Analyst
: Okay. That makes sense. And then I guess on life sciences, that was obviously, once again, really strong growth. Were there any shifts or unusual
items in that?
And then looking out at the next quarter, you're up against a really difficult compare because you had such a great quarter last year. How should
we think about lapping that?
Question: Glen Joseph Santangelo - Guggenheim Securities, LLC, Research Division - Analyst
: Chaim, I also wanted to follow-up on the inpatient side. I get it that the revenues are small today, but I was really trying to understand maybe how
the economic arrangements work with these customers and how that may be different from physicians to help us think about how the impact of
an Advent Health or First Health, for example, might change or augment your growth algorithm?
How should we think about those financial relationships?
Question: Glen Joseph Santangelo - Guggenheim Securities, LLC, Research Division - Analyst
: Okay. Maybe if I could just add a follow-up on an earlier question about the sales cycle. I think in the past, you said it takes about 90 days to bring
a physician online after you sell them. And if we sort of think about maybe April, May and June being sort of the height of the pandemic, is it
reasonable to think that as we look out to this next quarter that we may see the impact of maybe slower results in the height of the pandemic play
out in this next fiscal quarter?
I understand you don't want to give guidance, but I'm just trying to think about how the sales cycle may have impacted 2Q versus what we should
be expecting in 3Q?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
SEPTEMBER 09, 2020 / 12:30PM, PHR.N - Q2 2021 Phreesia Inc Earnings Call
Question: Sean Wilfred Dodge - RBC Capital Markets, Research Division - Analyst
: Chaim, maybe on the value proposition, going back to your comments around the strengthening Phreesia has seen in that post-pandemic here.
If we take a step back and assume volumes in payments at some point return to normal. Does -- or I guess, how does the enhancements you've
made, you've seen change your view on the potential long-term growth trajectory for the company. I guess do you come out of the pandemic
better than you went in? And how much better?
Question: Sean Wilfred Dodge - RBC Capital Markets, Research Division - Analyst
: Okay. That's great. And then maybe one on the cash collections, it looks like DSOs were down a little sequentially, but up still a fair amount
year-on-year. Is there something changing about revenue mix that's driving that? Or is that related to the deferral program, you all had mentioned
offering to some of your clients earlier on in the year?
Question: Sean Wilfred Dodge - RBC Capital Markets, Research Division - Analyst
: Okay. Is there any bookends you can put around maybe the proportion of clients or member clients that are taking part in that?
|
